Our portfolio has expanded to include testing for folate receptor alpha expression – learn more below.

ONC_ProviderSidebar

Connect with your sales representative

Fill out the form below to get in touch with your dedicated Myriad sales representative.

* Required field


Hidden Fields











Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.

Precise™ Oncology Solutions

Helping you find treatment clarity in cancer complexity

Precise Oncology Solutions allows you to order both germline and somatic testing in one seamless experience.

Precise™ Oncology Solutions:

Helping you find treatment clarity in cancer complexity

Precise Oncology Solutions allows you to order both germline and somatic testing in one seamless experience.

One simple order.
Comprehensive results.

Test for germline and somatic biomarkers in one order with Precise™ Oncology Solutions

Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive results for comprehensive germline testing, tumor profiling and companion diagnostic options, including HRD† testing with one order.

Precise, MyChoice CDx, MyRisk, BRACAnalysis CDx test boxes
Precise Oncology Solutions

GERMLINE

[FDA-Approved]

BRACAnalysis CDx®

[Non-FDA-Approved]

MyRisk™

HRD STATUS

[FDA-Approved]

MyChoice®CDx

IHC STAINS

TUMOR PROFILING

[Non-FDA-Approved]

Precise™ Tumor

† For patients with ovarian cancer.

* Precise Tumor, PD-L1, and FOLR1/FRα are powered by Intermountain Precision Genomics, a service of Intermountain Health. Precise Tumor and MyRisk are not approved by the FDA. FOLR1/FRα is an FDA-approved assay performed according to the intended use.

Get the genetic insights you need for treatment decisions

  • FDA-approved companion diagnostic options
  • Germline testing
  • Myriad HRD Status
  • Folate receptor alpha (FRα)
  • Tumor mutational burden
  • Microsatellite instability
  • PD-L1
  • 500+ genes including clinically actionable biomarkers for all solid tumor types

PARPi can cut disease progression or death for gBRCA patients graphic
PARPi can cut disease progression or death for gBRCA patients graphic

Precise Oncology Solutions

  • Tumor blocks sent to a single location
  • Identify patients who may benefit from PARP inhibitor therapy
  • Identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
  • Identify patients who may qualify for clinical trials
  • Optional participation in Molecular Tumor Board
  • PD-L1 available as an add-on (if Precise Tumor testing is ordered)
  • Optional enrollment in treatment registry (if Precise Tumor testing is ordered)

* Mirvetuximab is a product offered by ImmunoGen, Inc.

How to order

We’ve made it quick and simple to order all the necessary germline, somatic and HRD tests for each patient in one easy-to-use online portal experience.

Fill out a test request form in the Myriad Genetics provider portal.

Fill out a test request form in the Myriad Genetics provider portal.

Submit a blood or saliva sample for your patient’s germline test.

Submit a blood or saliva sample for your patient’s germline test.

Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for any somatic or HRD testing that is ordered.

Our laboratory processing staff will contact your pathology partner directly to obtain the tumor sample for any somatic or HRD testing that is ordered.

Clarity starts here

Each test result is reported out as it becomes available in the portal, and you will be provided with an easy-to-interpret summary sheet for all tests ordered for each patient. Upon receipt of all reports, you will receive a high-level summary sheet*, signaling all results are in, and allowing you to minimize your time in report review.

*Summary sheet includes information from both FDA-approved and non-FDA-approved tests and will be reflective of the specific tests ordered for each patient

Myriad Genetics Monthly Molecular Tumor Board

Join us each month to convene with clinical experts to provide state-of-the-art and evidence-based assessment of cases.

Topics can include:

  • Targeted therapy options based on genomic data
  • Prior lines of treatment and their impact on additional lines of therapy
  • Potential hereditary implications of genomic findings

This is not a CME event

BRACAnalysisCDx Logo

Intended use – PMA intended use statement for BRACAnalysis CDx

BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the most recently approved therapeutic product labeling.

Table 1: companion diagnostic indications

Tumor type Biomarker Therapy
Breast cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
  • TALZENNA® (talazoparib)
Ovarian cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
  • ZEJULA® (niraparib)
Pancreatic cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
Prostate cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)

This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108

LYNPARZA is a registered trademark of the AstraZeneca group of companies.

ONC_ProviderSidebar